These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3051529)
21. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Dyker AG; Lees KR Stroke; 1999 Sep; 30(9):1796-801. PubMed ID: 10471426 [TBL] [Abstract][Full Text] [Related]
22. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Bergamasco B; Benna P; Carolei A; Rasura M; Rudelli G; Fieschi C Funct Neurol; 1997; 12(1):33-43. PubMed ID: 9127122 [TBL] [Abstract][Full Text] [Related]
23. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. Scrutinio D; Cimminiello C; Marubini E; Pitzalis MV; Di Biase M; Rizzon P J Am Coll Cardiol; 2001 Apr; 37(5):1259-65. PubMed ID: 11300432 [TBL] [Abstract][Full Text] [Related]
24. Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. Ito E; Takahashi A; Yamamoto H; Kuzuhara S; Uchiyama S; Nakajima M; Intern Med; 2003 Sep; 42(9):793-9. PubMed ID: 14518664 [TBL] [Abstract][Full Text] [Related]
25. [Clopidogrel as basic therapy in high-risk stroke patients]. Mattle HP Praxis (Bern 1994); 2004 Aug; 93(34):1364. PubMed ID: 15468694 [No Abstract] [Full Text] [Related]
26. Clopidogrel: a review of its use in the prevention of atherothrombosis. Jarvis B; Simpson K Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738 [TBL] [Abstract][Full Text] [Related]
27. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Knudsen JB; Kjøller E; Skagen K; Gormsen J Thromb Haemost; 1985 Jun; 53(3):332-6. PubMed ID: 3901391 [TBL] [Abstract][Full Text] [Related]
28. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Haynes RB; Sandler RS; Larson EB; Pater JL; Yatsu FM Arch Intern Med; 1992 Jul; 152(7):1376-80. PubMed ID: 1627017 [TBL] [Abstract][Full Text] [Related]
29. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Collins R; Armitage J; Parish S; Sleight P; Peto R; Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485 [TBL] [Abstract][Full Text] [Related]
30. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Gent M; Blakely JA; Hachinski V; Roberts RS; Barnett HJ; Bayer NH; Carruthers SG; Collins SM; Gawel MG; Giroux-Klimek M Stroke; 1985; 16(3):416-24. PubMed ID: 2988158 [TBL] [Abstract][Full Text] [Related]
31. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. Lansky AJ; Tsuchiya Y; Brener M; Mehran R; Cristea E; Pietras C; Grines CL; Cox DA; Garcia E; Tcheng JE; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Leon MB; Moses J; Stone GW Catheter Cardiovasc Interv; 2008 Dec; 72(7):917-24. PubMed ID: 19016469 [TBL] [Abstract][Full Text] [Related]
32. Ticlopidine hydrochloride and prevention of stroke. Macko R West J Med; 1993 Aug; 159(2):182. PubMed ID: 8212686 [No Abstract] [Full Text] [Related]
33. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Jamieson DG; Parekh A; Ezekowitz MD J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203 [TBL] [Abstract][Full Text] [Related]
34. Ticlopidine: a new platelet aggregation inhibitor. Ito MK; Smith AR; Lee ML Clin Pharm; 1992 Jul; 11(7):603-17. PubMed ID: 1617911 [TBL] [Abstract][Full Text] [Related]
35. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Hankey GJ; Sudlow CL; Dunbabin DW Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426 [TBL] [Abstract][Full Text] [Related]
36. Ticlopidine hydrochloride: its current use in cerebrovascular disease. Bronstein KS; Chadwick LR Rehabil Nurs; 1994; 19(1):17-20. PubMed ID: 8159859 [TBL] [Abstract][Full Text] [Related]
37. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Mehta SR; Yusuf S; Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254 [TBL] [Abstract][Full Text] [Related]
38. Role of ticlopidine for prevention of stroke. Albers GW Stroke; 1992 Jun; 23(6):912-6. PubMed ID: 1595115 [TBL] [Abstract][Full Text] [Related]
39. Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)? Olson J; Huntington J J Fam Pract; 2001 Jul; 50(7):623. PubMed ID: 11485713 [No Abstract] [Full Text] [Related]
40. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study. Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]